SB's KYTRIL OVERTAKING GLAXO's ZOFRAN FOR CANCER CHEMO USE IN HOSPITALS AND CLINICS; GLAXO PRODUCT CONTINUES TO OUTSELL KYTRIL TWO-TO-ONE OVERALL
Executive Summary
SmithKline Beecham's Kytril (granisetron) is challenging Glaxo-Wellcome's Zofran (ondansetron) for leadership in the hospital and clinic chemotherapy submarket of the anti-nauseant category, SB Chairman Jan Leschly reported to a Bear Stearns investment seminar in New York on September 12.